Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety and efficacy of AZD4547 in combination with tislelizumab for urothelial carcinoma is in progress with status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• AZD4547
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Abbisko Therapeutics Co, Ltd | Conditions: Urothelial Carcinoma | Phase 2 | Status: UNKNOWN